As for HER-2-positive tumors, accounting for 10–30% of gastric cancer cases [7], one of the main concerns is the heterogeneity of this biomarker within the tumor, which may restrict patient selection and accrual for clinical trials. Here, ERBB2 is linked to gastric cancer.